Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.67 USD | -2.72% | -3.66% | +56.46% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
Business Summary
Number of employees: 30
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Human Enzyme Therapeutics
100.0
%
| 2 | 100.0 % | 1 | 100.0 % | -61.96% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 1 | 100.0 % | -61.96% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Chief Tech/Sci/R&D Officer | 56 | 14-01-31 | |
Mira Huyghe
PRN | Corporate Officer/Principal | - | Nov. 26 |
Deanna Nguyen
PRN | Corporate Officer/Principal | - | Nov. 26 |
Joshua Friedman
PRN | Corporate Officer/Principal | - | Nov. 26 |
General Counsel | 41 | 23-09-04 | |
Paul Fehlner
PRN | Corporate Officer/Principal | 61 | Nov. 26 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 37 | 23-06-21 |
Jeffrey Albers
BRD | Director/Board Member | 52 | Nov. 26 |
Peter Harwin
BRD | Director/Board Member | 38 | 23-06-21 |
Laurie Stelzer
BRD | Director/Board Member | 56 | Nov. 26 |
Director/Board Member | 34 | 23-06-21 | |
Mark Mckenna
BRD | Director/Board Member | 44 | Jan. 31 |
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 271,625 | 0 | 0 | 91.03 % |
Stock B | 1 | 50,782,384 | 46,227,440 ( 91.03 %) | 0 | |
Stock C | 0 | 437,037 | 0 | 0 |
Company contact information
Spyre Therapeutics, Inc.
Building 17 221 Crescent Street
02453, Waltham
+617 651 5940
http://www.aeglea.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.46% | 1.76B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+2.44% | 13.39B | |
+27.89% | 11.1B |
- Stock Market
- Equities
- SYRE Stock
- Company Spyre Therapeutics, Inc.